n INTRODUCTION A xial spondyloarthritis (axSpA) is an umbrella term defining an early age onset chronic inflammatory disease, which, if undiagnosed and untreated, can result in permanent damage and lifelong disability (1, 2) . AxSpA defines the entire spectrum of axial skeleton involvement spanning from ankylosing spondylitis (AS) to forms that have not yet or may never develop radiographic sacroiliitis, which fall under the category of non-radiographic axSpA (nr-axSpA) and which are often associated with bone oedema signs on spine magnetic resonance imaging (MRI) (3) . The term radiographic axSpA (r-axSpA) is used instead for AS by studies whose selection criteria were based on the Assessment of SpondyloArthritis International Society (ASAS) one (1) . These classification criteria seem to be able to identify patients with early stages of suspected axSpA. In fact, as far 21, 23) . Recent studies have focused on the role of other biomarkers to diagnose early-stage axSpA, to evaluate DA, and to predict patients at higher risk of worse outcome (16, 17) . Among these, matrix metalloproteinase (MMP) markers (and, in particular, MMP3) have also been considered possible biomarkers of DA given the correlation between MMP3 and CRP, DA and functional indices, such as BAS-DAI and Bath Ankylosing Spondylitis Functional Index (BASFI) (17, (24) (25) (26) , and of the radiographic progression in AS patients (27) . Although serum MMP3 represents a reliable parameter of DA, there is often no correlation with inflammatory MRI findings (26) . The aim of the current study was to examine some serological biomarkers, clinical and imaging parameters and DA indices in patients with early axSpA who were participating in the Italian arm of the SpondyloArthritis Caught Early (SPACE) study.
n MATERIALS AND METHODS

Patients
Patients who were at least 16 years old, suffering with inflammatory low back pain (LBP) (≥3 months, ≤2 years, onset <45 years) of unknown origin and referred to a rheumatologist were included in the Italian arm of the SPACE study which is an on-going observational cohort study that was originally launched at the Leiden University Medical Centre (LUMC, Holland) in January 2009, in collaboration with Rheumatology Unit of the University of Padua Medical Center (Italy) since March 2012. Patients qualifying for the study, in accordance with the ASAS criteria (1), were assessed following a specific protocol including physical examination, laboratory tests, SIJ/spine plain radiographs and MRI, questionnaires' regarding DA and functional state. The SpA features considered for diagnosis in accordance with the ASAS criteria (1) were radiographic sacroiliitis (modified New York = mNY criteria = bilateral grade ≥2 or unilateral grade ≥3), sacroiliitis on MRI (presence of ≥2 inflammatory as imaging data are concerned, they include the presence of sacroiliitis on MRI or X-rays in addition to one SpA feature for patients with onset of chronic low back pain (LBP) at or before 45 years. Conventional radiographs of sacroiliac joints (SIJ) (4), which are frequently used to detect sacroiliitis, do not appear to provide adequate information to formulate an early diagnosis (1, 4) . MRI can, instead, detect inflammatory lesions of SIJ in patients with early-onset axSpA without radiographic evidence of sacroiliitis (5, 6) . Recently, several studies have focused on biomarkers that could facilitate early diagnosis and identify individuals at higher risk of developing the disease (7) (8) (9) . Tumor necrosis factor α (TNFα) is a crucial cytokine that plays an essential role during the inflammatory response in SpA (10) . According to recent findings, the (IL)-23/IL-17 immune axis also appears to play an important role in its pathogenesis (11) (12) (13) (14) (15) . Several investigators have begun to examine serum and plasma biomarkers to assess their association with disease activity (DA) (16, 17) , since erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), commonly considered acute-phase proteins reflecting systemic inflammation, often prove to be unrelated to inflammation in axSpA (18) (19) (20) . Higher CRP levels in patients with r-axSpA with respect to their nr-axSpA peers (21, 22) have been described. Although CRP is not elevated in a large percentage of patients with active axSpA, it is widely considered a reliable parameter of DA and is correlated with the Ankylosing Spondylitis disease activity score (ASDAS) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). As CRP is moderately correlated with MRI signs of inflammation, it can be considered an efficacious tool for assessing DA and treatment response and for predicting further structural disease progression (16, 17, 20, 21) . Baseline CRP levels represent a strong predictor of radiographic structural damage progression, and, in particular, of the transition from nr-axSpA to AS (20, Biomarkers, imaging and disease activity indices in patients with early axial spondyloarthritis ORIGINAL PAPER lesions highly suggestive of axSpA on a single slice or one lesion on ≥2 consecutive slices), Human Leukocyte Antigen HLA-B27 positivity, positive family history for SpA, inflammatory (I)BP, psoriasis, peripheral arthritis, dactylitis, heel enthesitis, uveitis, inflammatory bowel disease (IBD), good response to non-steroidal anti-inflammatory drugs (NSAIDs) and elevated CRP or ESR. Only patients diagnosed with axSpA by two expert rheumatologists (RR and ML) were considered eligible for the study. All clinical, imaging, DA and serological indices considered were assessed at baseline, a time during which all the patients were being treated with only NSAIDs and not with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) or biologics. The study design was approved by the local ethics committee in accordance with the principles of the Declaration of Helsinki; informed consent was obtained from all of the eligible participants. The patients' X-rays and MRI images were scored independently by two expert readers (SV and LC), and the patients were classified, in accordance with the ASAS criteria for axSpA (1), into three patient cohorts: those fulfilling the mNY criteria for radiographic sacroiliitis (r-axSpA), those without signs of radiographic sacroiliitis but with signs of active sacroiliitis on MRI (nr-axSpA MRI SIJ+), those with positive HLA-B27 and with ≥2 additional SpA features but without signs of sacroiliitis on MRI or plain radiographs or those with ≥2 additional SpA features, negative HLA B27 and signs of BME on spine MRI (in accordance with ASAS/OMERACT criteria) (28) -(nr-axSpA MRI SIJ-/uSpA). Patients with suspected axSpA who did not fulfill the ASAS criteria and did not present any bone oedema signs on spine and pelvis MRI were excluded. The protocol for acquiring the MRI and plain radiograph images and for classifying clinical and clinimetric indexes (Bath Ankylosing Spondylitis Metrology Index (BASMI) and Maastricht Ankylosing enthesitis Spondilities Score (MASES), functional indices of disease activity BASDAI, BAS-FI; Visual Analogue Scale (VAS pain); VAS night pain, disease activity VAS; Bath Ankylosing Spondylitis Patient Global Score (BASG1); BASG2; Health Assessment Questionnaire (HAQ); Ankylosing Spondylitis disease activity score (ASDAS)) have been described elsewhere by Lorenzin et al. (29) . As explained, the MRI images were analyzed in accordance with the ASAS/EULAR criteria (5, 6) and the Spondyloarthritis Research Consortium of Canada (SPARCC) score (30, 31) , while spine X-Rays and SIJ X-Rays were scored in accordance with the Stoke Ankylosing Spondylitis Spinal Score (SASSS) system modified by Creemers (mSASSS) (32) and the NY criteria (4).
Serological evaluation ESR [normal range 0-15 mm/h] and CRP
[normal range 0-6 mg/L] values were determined. Serum ultrasensitive CRP (hs-CRP), (Research & Diagnostic Systems, Inc., expressed in mg/L, with a lower limit of detection of 0 mg/L); MMP3, (Quantikine MMP3 R&D Systems Europe, expressed in ng/mL, with a lower limit of detection of 0 ng/mL); IL-22, IL-17 and IL-23 (R&D Systems Europe, expressed in pg/mL, with lower limit of detection respectively of 5 pg/mL, 17 pg/mL, of 20 pg/mL) were assessed using an enzymelinked immunosorbent assay (ELISA). Serum for the assays was separated by centrifugation at 3000 rpm for 10 min and stored at -80°C. All blood samples were analyzed twice using the same method. Biomarkers, imaging and disease activity indices in patients with early axial spondyloarthritis ORIGINAL PAPER and DA indices, biomarkers and imaging scores at baseline are outlined in Table I . There were significant differences, according to the Kruskal Wallis (ANOVA) test, in the cohorts as far as the prevalence of radiographic sacroiliitis, active sacroiliitis on MRI and the SPARCC SIJ scores was concerned (Table I ). There were no differences in the serological markers (ILs, MMP3 and hsCRP) at baseline in the three groups. The ILs remained below detection levels in all of the cohorts. As expected, significant correlations were found between some clinical indices (BASFI, BASG1, BASG2, VAS) and between clinical and DA indices (BASDAI, ASDAS) (data not shown). The correlations between the clinical indices, MMP-3 and IL-22 are outlined in Table  II; Table III 
Statistical analyses
ORIGINAL PAPER
shown to assess DA or to predict outcome in axSpA. DA assessment and monitoring has for the most part been limited to patients' self-reports that do not necessarily correlate with MRI-detected inflammation or CRP levels. TNFα is a crucial cytokine that plays an essential role during the inflammatory response in SpA (10) via the up-regulation of adhesive molecules, lymphocyte activation, fibroblast proliferation and the production of the main pro-inflammatory cytokines. TNFα levels are significantly higher in AS patients with respect to subjects with non-inflammatory back pain or healthy controls (10) . Although it is not a reliable biomarker of DA, TNF-α assessment is considered a step forward in axSpA management that has significantly improved patient outcome (33) . Appropriate anti TNFα treatment can modify disease progression in axSpA as well as in nraxSpA (34, 35) . Although not confirmed by all studies (14) , in addition to TNFα, the IL-23/IL-17 immune axis appears to be an important pathway in the pathogenesis of SpA and in DA (11) (12) (13) (14) (15) 36) . IL-17 is the signature pro-inflammatory cytokine of a unique subset of T-helper cells, called Th17. Th17 cells differentiate from naïve T cells in a multistep process depending, first of all, on the presence of TGF-β, IL-6 and IL-1 inducing the expression of the Th17 master transcription factor called ROR-C. Another pro-inflammatory cytokine, IL-23 is crucial for stabilizing the Th17 phenotype and the expansion of Th17 populations. Other cells of both the adaptive and innate immune systems are activated by IL-23 and capable of producing IL-17 (11) (12) (13) (14) (15) . These findings have led to defining the IL-23/IL-17 axis involved in mucosal and skin barrier function and in defense against germs, as well as playing a role in the pathogenesis of autoimmune and several inflammatory diseases, such as axSpA (37) . The number of IL-17+T cells in peripheral blood is higher in AS patients with respect to that in healthy individuals (12, 37) . Interestingly, the number of IL-17 peripheral T cells is likewise higher in patients with early active axSpA both with and without MRI abnormalities (12) .
IL-17 is up-regulated in facet joints (38) as well as in the blood circulation (39) of AS patients with respect to subjects with degenerative lesions or healthy controls. Although IL-23 serum levels (14, (40) (41) (42) and IL-23 expression in the subchondral bone marrow from the facet joints (26) are up-regulated in AS patients, no correlation has been found with MRI inflammation or clinical DA (24) . As IL-17 and IL-23 levels fall significantly in responders to anti-TNFα drugs and rise in non-responders (41), both cytokines (IL-17, IL-23) are considered promising therapeutic targets (42, 43) . In addition, IL-22 interconnected with IL-17 and Th17 cells is elevated in patients with AS (43) . When IL-17, IL-22 and IL-23 were examined in our patients, they were found to be below detection levels in all three patient cohorts. The absence of any significant differences in the serum biomarker concentrations of the patients studied can probably be explained, firstly, by the patients' early disease stage (inflammatory low back pain ≥3 months and <2 years) and, secondly, by the small sizes of the subgroups. In fact, the low number of patients studied should be considered the study's major limit. We would also underline that, in accordance with ASAS criteria, the inclusion criteria of patients for this study were primarily the presence of inflammatory LBP and clinical/immunogenetic and imaging SpA features, and only later the three cohorts were the three cohorts classified in accordance with the imaging data features (presence or absence of SIJ involvement in MRI and X-Rays and of spine involvement in MRI). We can also hypothesize al posto di we could also conjecture that the absence of elevated serum levels of inflammatory markers such as CRP and ESR could be explained by the fact that the inflammation was restricted to specific tissue compartments and did not extend to the systemic circulation and/or lymphoid organs in axSpA. In fact, other studies have reported that the immunopathology of tissues and inflammatory alterations are not always reflected in the peripheral blood compartment (44, 45) . The findings outlined here are similar to those (49) . No significant correlations were instead found between skin involvement and serum levels of IL-22 in those of our patients who had only minor skin involvement or onicopathy with PASI <1. Higher IL-22 levels even in the axial form of SpA could suggest that it plays a role in active sacroiliitis. In accordance with some published reports, a significant correlation between inter-and intra-clinical and DA indices and between ESR and hs-CRP was also noted (16, 17, 47) . The correlation between serological MMP3 levels and mSASSS, indicative of the role of metalloproteinases in the bone formation process, was an interesting finding and in accordance with data outlined by Maksymowych et al. (47) who reported that independently of other indices, serum MMP3 levels were able to predict two-year radiographic progression in the 97 axSpA patients studied. Our data also showed that MMP3 is correlated with inflammatory markers (hs-CRP and ESR) and, in agreement with previous studies, it is increased in the serum of patients with active axSpA (24, 26, 27, 47) . The correlations between mSASS values and serum biomarkers require further evaluation by prospective studies. Some authors have reported a correlation between serum MMP3 levels and functional and DA indices (BASFI and BASDAI) (27, 47) . It has been shown that MMP3 correlates with DA indices even in psoriatic arthritis (PsA) (49 n CONCLUSIONS Significant differences in clinical severity, DA indices, and biomarker levels were not found in the three cohorts of patients diagnosed with early axSpA and presenting different types of axial involvement (presence or absence of radiographic sacroiliitis and of active sacroiliitis on pelvic MRI) studied. ILs, MMP3 and hs-CRP values were not significantly higher in any of the cohorts and were not correlated to radiographic SIJ involvement. A significant correlation between IL-22 and some DA indices and between MMP3 and hs-CRP was instead noted. The importance of diagnosing and treating axSpA early has been highlighted by numerous studies. Although the utility of some genetic and serological markers in diagnosing AS and axSpA, monitoring DA, and predicting patients at risk of poor outcome has been investigated by many researchers, ESR and CRP continue to prove inadequate in monitoring SpA activity (46) . The data outlined here suggest that peripheral blood compartment alterations do not reflect disease processes driving axial spondyloarthritis. As pointed out, the study's major limit is linked to the small numbers of patients studied and to the early disease stage (low back pain ≥3 months, ≤2 years, onset < 45 years). Further studies are, of course, required to assess the validity and reproducibility of the DA biomarkers considered here in identifying and monitoring early stages of axSpA. 
